Navarrete-Dechent C, et al. - Using the key words “dermatofibrosarcoma” or “dermatofibrosarcoma protuberans” AND “therapy” AND “imatinib,” a systematic review on the PubMed and Embase databases were conducted for articles published from September 2002 through October 2017 to assess the usefulness of imatinib for treating dermatofibrosarcoma protuberans (DFSP). For this investigation, researchers included studies of adults with histologically proven DFSP treated with imatinib as monotherapy or as an adjuvant or neoadjuvant therapy to surgery. Using descriptive statistics, the extracted data were analyzed. Adverse events were present in at least 73.5% of cases and severe adverse events were present in 15.1% of cases. There is no difference between daily doses of 400- or 800-mg. Complete response was seen in 5.2% of patients, partial response in 55.2%, stable disease in 27.6%, and progression in 9.2%. In patients with DFSP who are not surgical candidates owing to disease extension or significant cosmetic or functional impairment, imatinib is a useful directed therapy.